155 related articles for article (PubMed ID: 35042128)
1. Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study.
Chornenki NLJ; Siegal DM; Qamar K; Woolgar S; Rangarajan S; Karampatos S; Leong DP; Hillis CM
Leuk Res; 2022 Feb; 113():106788. PubMed ID: 35042128
[No Abstract] [Full Text] [Related]
2. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
[TBL] [Abstract][Full Text] [Related]
3. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Michiels JJ; Pich A; De Raeve H; Gadisseur A
Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
[No Abstract] [Full Text] [Related]
4. Current treatment of myeloproliferative neoplasias: three scenarios.
Xicoy B; Zamora L
Med Clin (Barc); 2020 Feb; 154(4):131-133. PubMed ID: 31351663
[No Abstract] [Full Text] [Related]
5. Pediatric Myeloproliferative Neoplasms.
El-Sharkawy F; Margolskee E
Clin Lab Med; 2021 Sep; 41(3):529-540. PubMed ID: 34304780
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
7. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
8. An addition to geographic hematology: chronic myeloproliferative diseases are infrequent in Mexican Mestizos.
Ruiz-Argüelles GJ; López-Martínez B; Lobato-Mendizábal E; Ruiz-Delgado GJ
Int J Hematol; 2002 Jun; 75(5):499-502. PubMed ID: 12095150
[TBL] [Abstract][Full Text] [Related]
9. Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment.
Breccia M; Palandri F; Luciano L; Benevolo G; Bonifacio M; Caocci G; Castagnetti F; Palumbo GA; Iurlo A; Landi F
Ann Hematol; 2018 May; 97(5):745-754. PubMed ID: 29468276
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.
Frederiksen H; Farkas DK; Christiansen CF; Hasselbalch HC; Sørensen HT
Blood; 2011 Dec; 118(25):6515-20. PubMed ID: 22039256
[TBL] [Abstract][Full Text] [Related]
11. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
Appelbaum FR
Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
[TBL] [Abstract][Full Text] [Related]
12. Interferon in the treatment of myeloproliferative diseases.
Silver RT
Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
[TBL] [Abstract][Full Text] [Related]
13. Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan.
Edahiro Y; Ochiai T; Hashimoto Y; Ichii M; Okatani T; Omura H; Nakajima K; Sasaki M; Ando J; Takaku T; Koike M; Izumiyama K; Hiraga J; Yano T; Usuki K; Ohtsuka E; Yokoyama K; Oyake T; Takahashi N; Nishida T; Nakao T; Fukuda Y; Akasaka T; Mugitani A; Ando M; Komatsu N
Hematology; 2024 Dec; 29(1):2340149. PubMed ID: 38626148
[TBL] [Abstract][Full Text] [Related]
14. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study.
Bankar A; Chan WC; Liu N; Cheung M; Alibhai S; Gupta V
Blood Adv; 2023 Sep; 7(17):5014-5026. PubMed ID: 37184988
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
17. Treatment of the myeloproliferative disorders with 32P.
Berlin NI
Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis and therapy of chronic myeloproliferative disorders].
Kimura A
Nihon Naika Gakkai Zasshi; 1998 Mar; 87(3):507-12. PubMed ID: 9577584
[No Abstract] [Full Text] [Related]
19. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
20. [Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion].
Usui N; Miyamura K; Arai A; Motomura S; Yokoyama M
Nihon Naika Gakkai Zasshi; 2007 Jul; 96(7):1434-55. PubMed ID: 17682432
[No Abstract] [Full Text] [Related]
[Next] [New Search]
